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Experimental studies show that vitamin D derivatives are potent anticarcinogenic factors. Epidemiological observations support this,
and vitamin D sufficiency has been hypothesised to be an important risk-reducing factor in several forms of cancer. Vitamin D level
exhibits seasonal variations. In the present work, we have investigated the effect of the season of diagnosis on the risk of death among
Hodgkin’s lymphoma patients diagnosed in Norway between 1964 and 2000. Risk estimates were calculated as relative risk (RR), with
95% confidence intervals (95% CI), using Cox regression model. Epidemiological data for this period indicate that season of diagnosis
is a strong prognostic factor for Hodgkin’s lymphoma, with E20% lower case fatality for patients diagnosed during autumn vs winter
diagnosis (RR¼0.783, 95% CI, 0.62 to 0.99; P¼0.041). Notably, the improved autumnal survival rate was higher than 60%
(RR¼0.364, 95% CI,  0.15 to 0.87; P¼0.025) for patients younger than 30 years. This finding may be related to higher endogenous
levels of vitamin D in autumn, with a favourable influence on the conventional therapy.
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Ultraviolet B radiation from the sun contributes strongly to the
vitamin D status in humans. Norway (581–711N) has pronounced
seasonal variation in the UV fluence rate. During the summer
season, the UV radiation is moderately strong, while during the
winter season, practically no vitamin D is generated by UV
radiation (Holick, 1994a). The maximal concentration of calcidiol
(25-hydroxyvitamin D3), which has been found in July–September
(Lund and Sorensen, 1979; Vik et al, 1980; Brot et al, 2001), is
about 50% higher than the baseline level measured during winter,
as illustrated in Figure 1D.
Since it is known that vitamin D derivates can modulate
proliferation and differentiation of cancer cells (Zehnder et al,
2001; Zittermann, 2003) and since the serum level of the vitamin D
metabolite calcidiol is almost 50% higher in the summer than in
the winter season, we wanted to investigate whether the prognosis
of malignant diseases in the Norwegian population might be
related to the season of their diagnosis. We have hypothesised that
the endogenous level of calcidiol at the time when the conventional
therapy is started is of therapeutic or prognostic significance.
Our suggestion of a relationship between the calcidiol level
and cancer prognosis is supported by a number of publications
showing a north–south gradient of cancer incidence and/or death
rates in many countries in the northern hemisphere (Garland et al,
1990; Gorham et al, 1990; Hanchette and Schwartz, 1992; John
et al, 1999; Grant, 2002, 2004; Grant and Garland, 2004; Tuohimaa
et al, 2004). Practically all investigators are of the opinion that this
gradient is related to sun-induced vitamin D3 in skin.
We have recently shown that sunlight may improve the
prognosis of breast, colon and prostate cancer (Robsahm et al,
2004), which all represent different entities of adenocarcinomas,
and for which surgery and/or radiation represent the main
therapeutic modalities utilised with curative intent.
In the present study, we estimated the outcome of patients
with Hodgkin’s lymphoma as a function of the season in which
the malignancy was diagnosed. Hodgkin’s lymphoma is a
malignant lymphoproliferative disease, which, unlike carcinomas
of the breast, colon or prostate, is often associated with systemic
manifestations like fever and extensive weight loss. Moreover, for
the last decades, combined modality strategies, using combination
chemotherapy followed by radiation as supplementary therapy for
residual disease, have been the therapy of choice for the majority
of the disease stages (Diehl et al, 2004).
Hodgkin’s lymphoma has a biphasic age-specific incidence
pattern (Cartwright and Watkins, 2004; Provencio et al, 2004) and
younger patients generally have a more favourable prognosis than
the older ones (Provencio et al, 2004). Hence, in the present study,
we analysed the outcome in patients younger and older than 30
years of age separately.
PATIENTS AND METHODS
Data collection
The population-based Cancer Registry of Norway has been
recording all cancer cases since 1953. The registration is based
on the unique personal identification number (11 digits) assigned
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yto all Norwegian inhabitants alive in 1964 and born ever since. The
Registry is also notified on all the deaths in which cancer was the
underlying disease.
In the present study, based on cases from 1964 to the end of 2000,
3139 Hodgkin’s lymphoma cancer patients were diagnosed. All were
born between 1900 and 1966. The patients were followed until death,
emigration or 31 December 2000, whichever occurred first. The
mean time of the follow-up from date of diagnosis was 123 months.
Variables and statistical analysis
Based on the age-specific incidence pattern of Hodgkin’s
lymphoma in the Norwegian population (Hansen et al, 2005),
the series of patients were stratified in two age groups: 0–29 years
(950 cases, mean age 2270.32) and 30þ years (2189 cases, mean
age 53.670.16).
Seasonal trends in the epidemiology of Hodgkin’s lymphoma
were estimated. The time points for diagnosis were grouped in four
seasons: winter (1st of December–29th of February), spring (1st of
March–31st of May), summer (1st of June–31st of August) and
autumn (1st of September–30th of November).
The number of incident cases corresponding to each season was
collected. The fatality among cases was estimated as relative risk
(RR) of cancer death, defined as the ratio between mortality among
patients diagnosed in different seasons. The RR for winter was
designated as the reference risk, and 95% confidence intervals
are given to indicate the level of significance. Estimated RR was
adjusted for age at diagnosis, birth cohort, decade of diagnosis,
residential region and sex. Owing to the lack of data in The Cancer
Registry, adjustment for stage at diagnosis was possible only for
the patients diagnosed after 1993. This analysis included 602
patients, and adjustment for stage did not affect the case fatality
according to season of diagnosis. However, similar stage-adjust-
ments performed previously for other malignancies (bladder and
ovary cancer, data not shown) resulted in unchanged risk
estimates according to season of diagnosis.
All analyses were performed for the first 18 and 36 months of the
follow-up, as well as for the overall follow-up.
All calculations were carried out using the SPSS program (SPSS
Inc.). The Cox regression method was chosen to estimate the effect
of season of diagnosis on the relative risk of cancer death.
RESULTS
Table 1 shows the number of new cases and the death risk
estimates as a function of season at diagnosis for Hodgkin’s
lymphoma. No seasonal variation in the number of new cases
of Hodgkin’s lymphoma was observed. However, a significant
seasonal effect on case fatality was found, as reflected by the
lowered death risk estimates (RR 0.78–0.84, regardless of the time
point of follow-up) for cases diagnosed during autumn (Table 1,
Figure 1A). Closely similar patterns of relative death risk (RR
0.84–0.87) were observed upon analysis of the older age group
(30þ years) separately (Table 1, Figure 1C). Within the younger
category of patients (0–29 years), the seasonal effect on outcome
after 18 and 36 months of follow-up was remarkable (RR 0.36
and 0.50, respectively) (Figure 1B). The seasonal impact on overall
survival of this age group, however, did not differ from the case
fatality patterns observed within the entire population of
Hodgkin’s lymphoma patients.
DISCUSSION
Since very few types of food naturally contain vitamin D, solar
UVB radiation is the main source of vitamin D3 for humans
(Holick, 1994b; Zittermann, 2003). During exposure to solar
radiation, 7-dehydrocholesterol (provitamin D3) in epidermis and
dermis absorbs UVB radiation and is converted to previtamin D3,
which, in turn, is isomerised in the skin to vitamin D3. Once
formed in the skin, vitamin D3 enters the circulation and is
metabolised in the liver by 25-hydroxylase to 25-hydroxyvitamin
D3 (calcidiol), which is further converted in the kidney by 1a-
hydroxylase to 1a,25-dihyroxyvitamin D3 (calcitriol). This active
metabolite binds to the nuclear receptors in the intestine, bone and
kidney to perform the calcaemic function in the bone and mineral
metabolism (Holick, 1994b).
Notably, a wide variety of normal and malignant tissues express
the enzymatic system that produces calcitriol as well as receptors
to use it in an autocrine fashion, to regulate cell proliferation
and differentiation (Zehnder et al, 2001; Zittermann, 2003). This is
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Figure 1 Seasonality of death risk from Hodgkin’s lymphoma in Norway
in 1964–2000. Series of Hodgkin’s lymphoma patients were analysed by
age groups. Relative risk of death by season of diagnosis (winter is the
reference season) is shown for the all ages group (A), 0–29 years group
(B) and þ30 years group (C). Data were analysed for the first 18 (n) and
36 (.) months from diagnosis as well as for the overall period (end of
registration) (&). Averaged serum calcidiol levels reported for Tromsø
(691N) (Vik et al, 1980) and Denmark (54–581N) (Lund and Sorensen,
1979) are given (D).
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analogues, as adjuvant therapy in different malignancies.
Since the production of previtamin D3 in the skin is directly
related to the level of solar UVB radiation, one may expect that
a decrease in the UVB fluence will be reflected in a decrease in
the endogenous level of vitamin D3. During winter, when the solar
elevation is low, radiation from the sun has a longer path through
the ozone layer, which efficiently absorbs radiation in the UVB
region. Therefore, the summer/autumn values of serum calcidiol
are 40–100% higher than the winter values in most white
populations both for young (Vik et al, 1980) and elderly
individuals (Webb et al, 1990; van der Wielen et al, 1995; Perry
et al, 1999).
We have previously found seasonal variation in the prognosis
of breast, colon and prostate adenocarcinomas (Moan et al, 2004;
Robsahm et al, 2004). The prognosis was found to be significantly
better for summer/autumn diagnosis, which we tentatively
attributed to the 50% higher calcidiol levels in these seasons as
compared with winter.
The present work shows that season of diagnosis has an even
stronger impact on prognosis in Hodgkin’s lymphoma, particu-
larly in young patients. For patients younger than 30 years, the
death rate after 18 months of follow-up was almost 60% lower for
autumn diagnosis than for winter diagnosis, while the correspon-
ding number was smaller (E15%) for patients older than 30 years.
Three observations argue against the fact that the present findings
are due to systematic errors in the cancer registration. Firstly, a
similar trend has been found for prostate, breast and colon cancer
(Moan et al, 2004; Robsahm et al, 2004). Secondly, the number of
incident cases has no seasonal variation, neither for the cancer
forms previously studied (Moan et al, 2004; Robsahm et al, 2004)
nor for Hodgkin’s lymphoma. Thirdly, no significant seasonal
variation in relative risk of death was found for ovary and bladder
cancer (data not shown).
As in our previous studies (Moan et al, 2004; Robsahm et al,
2004), the death risk for Hodgkin’s lymphoma patients was found
to have a minimum for the cases diagnosed during autumn. This is
slightly after the time of maximal serum values for calcidiol. If we
assume that the observed effect is an adjuvant one of vitamin D on
standard therapy in Hodgkin’s lymphoma, the discrepancy in time
between the curve for calcidiol and that for death rate is even
larger since there is often a short delay between diagnosis and start
of therapy. However, since for statistical reasons we have only four
seasonal points on the death rate curves, we cannot determine the
exact time point for minimal risk. The slight shift of the calcidiol
curve from midsummer towards autumn is presumably related
to the delay between photoisomerisation of 7-dehydrocholestrol
in skin and appearance of calcidiol in serum (Zittermann,
2003). Another factor to consider is that the summer vacation
in Norway is not centred around midsummer but rather in
July–August.
Other possible explanations of the findings should certainly not
be overlooked. Owing to vacation, the general health condition
may be better at the end of the summer. The intake of vegetables
and antioxidants, which is hypothesised to reduce cancer risk
(Talalay and Fahey, 2001; Genkinger et al, 2004), may be higher
in summer than in winter. However, the data for ovary cancer
and bladder cancer (data not shown) argue against these
explanations.
The relative seasonal variation of the death rates in Hodgkin’s
lymphoma patients younger than 30 years appeared to decrease
with increasing observation time. For most patients, particularly
in the younger population, the first-line therapy is applied with
curative intent. Hence, it is reasonable to believe that any
therapeutic effect of vitamin D is principally to delay disease
relapse when primary cure is not achieved.
We performed the analyses on patients groups stratified by age,
since it is known that sun-induced vitamin D production in the
skin is age dependent (MacLaughlin and Holick, 1985). The serum
level of calcidiol is almost four-fold higher after a given UVB
exposure for the age group 20–30 years than for the age group
62–80 years (Holick et al, 1989). This strongly supports the role of
vitamin D in the explanation of our data.
Epidemiologic studies suggest a seasonal pattern in the onset
of Hodgkin’s lymphoma, with the highest incidence rates around
March (Douglas et al, 1998), linking this to the ethiopathology of
the disease. Our data show a maximum of number of diagnosis
during winter (26.3%, data for young patients) and a nadir during
summer (22.5%). The low number of incident cases during
summer may be due to vacation. This hypothesis is supported
by similar patterns observed for other cancer types that do not
share similar ethiopathology with Hodgkin’s lymphoma (Robsahm
et al, 2004).
In conclusion, we have found that the prognosis of Hodgkin’s
lymphoma is significantly correlated with the season of diagnosis,
particularly for patients younger than 30 years. This seasonal effect
is presumably due to the vitamin D3 synthesis in skin during sun
exposure. The present findings should encourage further investi-
gations of the possible adjuvant role of vitamin D derivatives in
cancer therapy. So far, mainly calcitriol derivatives have been
tested in cancer therapy (Trump et al, 2004; Beer and Myrthue,
2004), probably because calcitriol is known to be the most potent
vitamin D metabolite involved in the systemic calcium homeo-
stasis (Holick, 1994b; Beer and Myrthue, 2004). However, serum
Table 1 Number of incident cases and relative risk (RR) of cancer death analysed by season of diagnosis and age groups at diagnosis
RR death
Number of new cases (n¼3139) All ages 0–29 years 30+ years
Season of
diagnosis
0–29 y.o. (n¼950,
mean age 22,
s.e.
a 0.32)
30+ y.o. (n¼2189,
mean age 53.6,
s.e.
a 0.16) RR
b 95% CI
c P
d RR
b 95% CI
c P
d RR
b 95% CI
c P
a
Winter 250 570 1.000 1.000 1.000
Spring 240 543 0.953 0.75, 1.19 0.67 0.965 0.49, 1.87 0.91 0.954 0.74, 1.21 0.7
Summer 214 515 0.881 0.69, 1.11 0.29 0.800 0.37, 1.70 0.56 0.898 0.70, 1.14 0.39
Autumn 246 562 0.783 0.62, 0.99 0.04 0.364 0.15, 0.87 0.02 0.841 0.65, 1.07 0.16
Test for trend
c 0.019 0.032 0.111
as.e.¼standard error of the mean.
bEstimated RR adjusted for age at diagnosis, birth cohort, decade of diagnosis, sex and place of residence.
c95% confidence intervals.
dP-value.
95% confidence intervals (CI) are given. Data for the 18 months follow-up are shown.
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increase during summer (Chesney et al, 1981). Our work indicates
that one should rather investigate calcidiol derivatives in view of
adjuvant cancer therapy.
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